<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157298</url>
  </required_header>
  <id_info>
    <org_study_id>D1692C00013</org_study_id>
    <nct_id>NCT02157298</nct_id>
  </id_info>
  <brief_title>Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.</brief_title>
  <official_title>A 16-week Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with
      inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and &lt; 11% will be
      enrolled into the wash-out phase or directly into the lead-in phase depending on whether the
      patient has been receiving an Oral antidiabetic drug (including Glucagon-Like Peptide-1
      agonists and excluding Thiazolidinedions) other than a Dipeptidyl Peptidase-4 inhibitor as
      part of the baseline treatment. Additional treatment with a concomitant Dipeptidyl
      Peptidase-4 inhibitor is allowed. And around 180 eligible patients in total will be
      randomized into the study with a 2:1 randomization scheme (i.e.120 patients into the
      dapagliflozin treatment group and 60 patients into the placebo treatment group. All subjects
      who completed a 16 weeks double-blind treatment period will shift to a 36 weeks open
      extension treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change in HbA1c Levels</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Weight</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Mean Daily Insulin Dose</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>dapagliflozin 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin tablet 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dapagliflozin tablet 5mg placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 5 mg</intervention_name>
    <description>Dapagliflozin, a blood glucose lowering drug. Oral dose</description>
    <arm_group_label>dapagliflozin 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet. Oral dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Diagnosis of Type 2 Diabetes according the criteria specified by the Japan Diabetes
             Society

          -  Japanese Men or women age ≥ 20 years at time of consenting.

          -  Stable (unless adjustment is required based on Fasting Plasma Glucose values) dose
             insulin* mono-therapy with the mean insulin [up to two types of insulin within
             authorized indication in Japan] dose of ≥ 0.2 IU/kg/day AND ≥ 15 IU/body/day over the
             past 8 weeks prior to enrolment.

          -  HbA1c ≥ 7.2% and &lt; 11% from the blood samples collected at Visit 1 (enrolment) and
             Visit 3, observed from the central laboratory

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of
             the Young, secondary diabetes mellitus or diabetes insipidus

          -  History of diabetic ketoacidosis.

          -  Thyroid-stimulating hormone and free T4 values outside normal range, observed from the
             central laboratory; an abnormal Thyroid-stimulating hormone value needs to be followed
             up with a free T4 test. Patients with abnormal free T4 values will be excluded at
             Visit 1

          -  Fasting Plasma Glucose &gt;240 mg/dL (twice in a row) despite the permitted dose
             adjustment of insulin therapy during washout period and lead-in period.

          -  Recent cardiovascular events in a patient.

          -  eGFR &lt;45 mL/min/1.73 m2 at Visit 3, observed from the central laboratory.

          -  History of unstable or rapidly progressing renal disease.

          -  History of unexplained microscopic or gross hematuria, or microscopic hematuria at
             Visit 1, confirmed by a follow-up sample at next scheduled visit, where according to
             the investigator a satisfactory evaluation of hematuria has not been conducted.

          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as
             aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or alanine
             aminotransferase (ALT) &gt;3x ULN, observed from the central laboratory at Visit 1.

          -  Total bilirubin &gt;2.0 mg/dL (34.2 μmol/L), observed from the central laboratory at
             Visit 1.

          -  Positive serologic evidence of current infectious liver disease including Hepatitis A
             viral antibody IgM, Hepatitis B surface antigen and Hepatitis C virus antibody,
             observed from the central laboratory.

          -  Haemoglobin &lt;10 g/dL (&lt;100 g/L) or 6.2 mmol/L for men; haemoglobin &lt;9.0 g/dL (&lt;90 g/L)
             or 5.9 mmol/L for women, observed from the central laboratory at Visit 1.

          -  History of chronic haemolytic anaemia or haemoglobinopathies (for example, sickle cell
             anaemia, thalassemia, sideroblastic anaemia). Mild haemolysis due to artificial heart
             valves or due to sickle cell trait is not an exclusion criterion except when
             haemoglobin levels are too low (as defined in haemoglobin criteria above).

          -  History of malignancy within the last 5 years prior to enrolment, excluding successful
             treatment of basal or squamous cell skin cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adachi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirosaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamakura-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mitaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese patients with type 2 diabetes with inadequate glycemic control on insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant enrolled: 06-Jun-2014; Last participant last visit of ST period: 02-Feb-2015; 266 participants were enrolled in 20 Japanese centers. 183 Japanese men or women aged &gt;=20 years with inadequate glycemic control (HbA1c levels of &gt;=7.2% to &lt;11.0%) with diet, exercise and on stable dose of insulin +/- DPP-4 inhibitor were treated.</recruitment_details>
      <pre_assignment_details>A 8-week wash-out period was applicable only for participants on ongoing anti-diabetic treatment at enrollment. A 2-week lead-in period was applicable for all participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during the short-term double-blind treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="9.83"/>
                    <measurement group_id="B2" value="57.6" spread="9.86"/>
                    <measurement group_id="B3" value="58.0" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.90" spread="15.663"/>
                    <measurement group_id="B2" value="71.89" spread="13.430"/>
                    <measurement group_id="B3" value="73.24" spread="14.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.89" spread="4.930"/>
                    <measurement group_id="B2" value="26.12" spread="3.485"/>
                    <measurement group_id="B3" value="26.64" spread="4.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.2" spread="11.83"/>
                    <measurement group_id="B2" value="92.3" spread="9.00"/>
                    <measurement group_id="B3" value="92.9" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percent of hemoglobin glycosylated</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.26" spread="0.792"/>
                    <measurement group_id="B2" value="8.52" spread="0.937"/>
                    <measurement group_id="B3" value="8.34" spread="0.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.70" spread="44.948"/>
                    <measurement group_id="B2" value="159.68" spread="38.001"/>
                    <measurement group_id="B3" value="160.36" spread="42.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calculated Mean Daily Insulin Dose</title>
          <units>IU/Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.87" spread="18.033"/>
                    <measurement group_id="B2" value="40.58" spread="16.764"/>
                    <measurement group_id="B3" value="38.76" spread="17.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DPP-4 Inhibitor Usage</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change in HbA1c Levels</title>
        <description>Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in HbA1c Levels</title>
          <description>Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
          <units>percentage of hemoglobin glycosylated</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" lower_limit="-0.67" upper_limit="-0.42"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.13" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(dapa) minus mean(placebo) = 0 versus alternative HA: mean(dapa) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose</title>
        <description>Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" lower_limit="-28.3" upper_limit="-15.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-8.4" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(dapa) minus mean(placebo) = 0 versus alternative HA: mean(dapa) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.301</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.2</ci_lower_limit>
            <ci_upper_limit>-12.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Weight</title>
        <description>Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Weight</title>
          <description>Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-0.9" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.2" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(dapa) minus mean(placebo) = 0 versus alternative HA: mean(dapa) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.255</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Mean Daily Insulin Dose</title>
        <description>Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mean Daily Insulin Dose</title>
          <description>Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and at least one post-baseline value up to week 16</population>
          <units>IU/Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" lower_limit="-1.21" upper_limit="-0.27"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.68" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(dapa) minus mean(placebo) = 0 versus alternative HA: mean(dapa) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0743</p_value>
            <p_value_desc>Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%</title>
        <description>Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) value</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%</title>
          <description>Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and Week 16 (LOCF) value</population>
          <units>percentage of participants</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="3.3" upper_limit="13.1"/>
                    <measurement group_id="O2" value="4.9" lower_limit="-0.7" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: proportion(dapa) minus proportion(placebo) = 0 versus alternative HA: proportion(dapa) minus proportion(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3727</p_value>
            <p_value_desc>Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Based on methodology of Zhang, Tsiatis &amp; Davidian and Tsitatis, Davidian, Zhang &amp; Lu, with adjustment with adjustment for baseline value and DPP-4</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.769</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious/serious adverse events on or after the first date of double-blind treatment and on or prior to the last day plus 4/30 days or up to follow-up visit if earlier, or up to and excluding the start date of open-label extension period if earlier.</time_frame>
      <desc>Participants were questioned at each study about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin 5 mg plus insulin alone or in combination with DPP-4 inhibitor</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo plus insulin alone or in combination with DPP-4 inhibitor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For HbA1c, FPG and TBW: excluding data after insulin up-titration and for Mean Daily Insulin Dose: including data after insulin up-titration were used. For participants who did not complete week 16 last observation carried forward (LOCF) was used.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yuji Ageishi</name_or_title>
      <organization>AstraZeneca K.K.</organization>
      <phone>+81-3-6268-2740</phone>
      <email>Yuji.Ageishi@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

